Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: From adults to children

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 397-405

  Kersting, Gisela ^a,b   Willmann, Stefan ^c   Würthwein, Gudrun ^a   Lippert, Jörg ^c   Boos, Joachim ^b   Hempel, Georg ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c BAYER AG   (Germany)

Author keywords

Chemotherapy; Etoposide; Modelling; Paediatrics; Pharmacokinetics; Simulation

Indexed keywords

BUSULFAN; CARBOPLATIN; CARRIER PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P INHIBITOR; LYMPHOCYTE ANTIBODY; MELPHALAN; NEUROTOXIN;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; IN VITRO STUDY; INFANT; LOW DRUG DOSE; MALE; MICHAELIS MENTEN KINETICS; MULTIPLE CYCLE TREATMENT; PHYSIOLOGY BASED PHARMACOKINETIC MODEL; PREDICTION; PRIORITY JOURNAL; SIMULATION; STATISTICAL MODEL; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ETOPOSIDE; FEMALE; HUMANS; INFANT; MALE; MELPHALAN; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN BINDING;

EID: 84856759079     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1706-9     Document Type: Article

References (46)

1. J Palle BM Frost G Gustafsson M Hellebostad J Kanerva E Liliemark K Schmiegelow G Lönnerholm 2006 Etoposide pharmacokinetics in children treated for acute myeloid leukemia Anticancer Drugs 17 1087 1094 17001183 10.1097/01.cad.0000231470.54288.49 1:CAS:528:DC%2BD28XpvFertr4%3D (Pubitemid 44454787)
2. MV Relling HL McLeod LC Bowman VM Santana 1994 Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin Clin Pharmacol Ther 56 503 511 7955814 10.1038/clpt.1994.171 1:STN:280: DyaK2M%2Fktlynug%3D%3D (Pubitemid 24370357)
3. JC Panetta M Wilkinson CH Pui MV Relling 2002 Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukaemia J Pharmacokin Pharmacodyn 29 171 188 10.1023/A:1019755608555 1:CAS:528:DC%2BD38XmtFShu7w%3D
4. S Urien F Doz C Giraud E Rey JC Gentet P Chastagner G Vassal N Corradini A Auvrignon P Leblond H Rubie JM Treluyer 2011 Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect Cancer Chemother Pharmacol 67 597 603 20490798 10.1007/s00280-010-1357-2 1:CAS:528: DC%2BC3MXitlalsrc%3D
5. GJ Veal M Cole J Errington AD Pearson M Gerrard G Whyman C Ellershaw AV Boddy 2010 Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients Cancer Chemother Pharmacol 65 1057 1066 19701749 10.1007/s00280-009- 1111-9 1:CAS:528:DC%2BC3cXjtlalsLk%3D
6. G Würthwein T Klingebiel S Krümpelmann M Metz K Schwenker K Kranz C Lanvers J Boos 2002 Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens Anticancer Drugs 13 101 110 11914647 10.1097/00001813-200201000-00012 (Pubitemid 34169533)
7. G Würthwein S Krümpelmann B Tillmann E Real P Schulze-Westhoff H Jürgens J Boos 1999 Population pharmacokinetic approach to compare oral and i.v. administration of etoposide Anticancer Drugs 10 807 814 10587290 10.1097/00001813-199910000-00003 (Pubitemid 30011827)
8. F Pein R Pinkerton P Berthaud K Pritchard-Jones G Dick G Vassal 2007 Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours Eur J Cancer 43 2074 2081 17716890 10.1016/j.ejca.2007.07.003 1:CAS:528:DC%2BD2sXhtVCitrzL (Pubitemid 47380364)
9. N Hijiya JC Panetta Y Zhou EP Kyzer SC Howard S Jeha BI Razzouk RC Ribeiro JE Rubnitz MM Hudson JT Sandlund CH Pui MV Relling 2006 Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia Blood 108 3997 4002 16917005 10.1182/blood-2006-05- 024414 1:CAS:528:DC%2BD28XhtlWqsrrO (Pubitemid 44913268)
10. GL Kearns SM Abdel-Rahman SW Alander DL Blowey JS Leeder RE Kauffman 2003 Developmental pharmacology-drug disposition, action, and therapy in infants and children N Engl J Med 349 1157 1167 13679531 10.1056/NEJMra035092 1:CAS:528:DC%2BD3sXnsV2jtbo%3D (Pubitemid 37122329)
11. S Haddad C Restieri K Krishnan 2001 Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans J Toxicol Environ Health A 64 453 464 11732696 10.1080/152873901753215911 1:CAS:528:DC%2BD3MXovVCrt7c%3D (Pubitemid 33139645)
12. AN Edginton FP Theil W Schmitt S Willmann 2008 Whole body physiologically-based pharmacokinetic models: their use in clinical drug development Expert Opin Drug Metab Toxicol 4 1143 1152 18721109 10.1517/17425255.4.9.1143 1:CAS:528:DC%2BD1cXhtVaisLzL
13. T Teorell 1937 The diffusion effect upon ionic distribution: II. Experiments on ionic accumulation Gen Physiol 21 107 122 10.1085/jgp.21.1.107 1:CAS:528:DyaA2sXmtVentg%3D%3D
14. KB Bischoff RL Dedrick DS Zaharko 1970 Preliminary model for methotrexate pharmacokinetics J Pharm Sci 59 149 154 5411336 10.1002/jps.2600590203 1:CAS:528:DyaE3cXpvVOmtw%3D%3D
15. KB Bischoff RL Dedrick DS Zaharko JA Longstreth 1971 Methotrexate pharmacokinetics J Pharm Sci 60 1128 1133 5127083 10.1002/jps.2600600803 1:CAS:528:DyaE3MXkvFKqurk%3D
16. N Benowitz KL Melmon M Rowland 1974 Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model Clin Pharmacol Ther 16 87 98 4210516 1:STN:280:DyaE2c3nslKjsA%3D%3D
17. AN Edginton W Schmitt B Voith S Willmann 2006 A mechanistic approach for the scaling of clearance in children Clin Pharmacokinet 45 683 704 16802850 10.2165/00003088-200645070-00004 1:CAS:528:DC%2BD28Xot1eksLs%3D (Pubitemid 43990570)
18. AN Edginton W Schmitt S Willmann 2006 Development and evaluation of a generic physiologically based pharmacokinetic model for children Clin Pharmacokinet 45 1013 1034 16984214 10.2165/00003088-200645100-00005 1:CAS:528:DC%2BD28XhtF2rurzP (Pubitemid 44436004)
19. J Li P Gwilt 2003 The effect of age on the early disposition of doxorubicin Cancer Chemother Pharmacol 51 395 402 12679882 1:CAS:528: DC%2BD3sXjsVOru7Y%3D (Pubitemid 36649136)
20. S Willmann S Lippert W Schmitt 2005 From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools Expert Opin Drug Metab Toxicol 1 159 168 16922658 10.1517/17425255.1.1.159 1:CAS:528:DC%2BD2MXmvVGhs7Y%3D
21. JC Shah JR Chen D Chow 1989 Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide Pharm Res 6 408 412 2748532 10.1023/A:1015935532725 1:CAS:528:DyaL1MXkvVeqtL4%3D (Pubitemid 19176085)
22. D Busse G Würthwein C Hinske G Hempel MF Fromm M Eichelbaum HK Kroemer FW Busch 2002 Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration Naunyn Schmiedebergs Arch Pharmacol 366 218 225 12172704 10.1007/s00210-002-0594-2 1:CAS:528:DC%2BD38XlvVCjs70%3D (Pubitemid 34994916)
23. T Rodgers D Leahy M Rowland 2005 Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J Pharm Sci 94 1259 1276 15858854 10.1002/jps.20322 1:CAS:528:DC%2BD2MXkvF2qtLs%3D (Pubitemid 40904190)
24. T Rodgers M Rowland 2006 Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J Pharm Sci 95 1238 1257 16639716 10.1002/jps.20502 1:CAS:528:DC%2BD28XlsFWlsrY%3D (Pubitemid 43874439)
25. T Rodgers M Rowland 2007 Mechanistic approaches to volume of distribution predictions: understanding the processes Pharm Res 24 918 933 17372687 10.1007/s11095-006-9210-3 1:CAS:528:DC%2BD2sXkslWgt7c%3D (Pubitemid 46675393)
26. J Boos S Krümpelmann P Schulze-Westhoff T Euting F Berthold H Jürgens 1995 Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 13 2954 2960 8523060 1:CAS:528:DyaK28XmslOmtg%3D%3D
27. T Kawashiro, et al. 1998 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes J Pharmacol Exp Ther 286 1294 1300 9732391 1:CAS:528: DyaK1cXmt1Gqs74%3D (Pubitemid 29135542)
28. Y Watanabe M Nakajima N Ohashi T Kume T Yokoi 2003 Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1 Drug Metab Dispos 31 589 595 12695347 10.1124/dmd.31.5.589 1:CAS:528:DC%2BD3sXjt1Ggt7g%3D (Pubitemid 36444168)
29. A Guo W Marinaro P Hu PJ Sinko 2002 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT) Drug Metab Dispos 30 457 463 11901101 10.1124/dmd.30.4.457 1:CAS:528:DC%2BD38Xis1Olsb4%3D (Pubitemid 34263832)
30. KR Hande 1992 Etoposide pharmacology Semin Oncol 19 Suppl 13 3 9 1492225 1:CAS:528:DyaK3sXisVKks7g%3D (Pubitemid 23056591)
31. WL Hayton 2000 Maturation and growth of renal function: dosing renally cleared drugs in children AAPS PharmSci 2 E3 11741219 1:STN:280: DC%2BD3MjgtVKqsw%3D%3D
32. PI Clark M Slevin 1987 The clinical pharmacology of etoposide and teniposide Clin Pharmacokinet 12 223 252 3297462 10.2165/00003088-198712040- 00001 1:CAS:528:DyaL2sXksFWiurc%3D (Pubitemid 17072058)
33. KR Hande SN Wolff FA Greco JD Hainsworth G Reed DH Johnson 1990 Etoposide kinetics in patients with obstructive jaundice J Clin Oncol 8 1101 1107 2348225 1:STN:280:DyaK3c3ntV2isg%3D%3D (Pubitemid 20200199)
34. JJ Holthuis 1988 Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics Pharm Weekbl Sci 10 101 116 3047665 10.1007/BF01959294 1:CAS:528:DyaL1MXh
35. M Pelekis LA Gephart SE Lerman 2001 Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds Regul Toxicol Pharmacol 33 12 20 11259175 10.1006/rtph.2000.1436 1:CAS:528:DC%2BD3MXhvFKjtL4%3D (Pubitemid 32242943)
36. K Price S Haddad S Krishnan 2003 Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children J Toxicol Environ Health A 66 417 433 12712630 10.1080/15287390306450 1:CAS:528: DC%2BD3sXivFWntb8%3D (Pubitemid 36269795)
37. PR Gentry TR Covington HJ Clewell 3rd 2003 Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation Regul Toxicol Pharmacol 38 1 16 12878049 10.1016/S0273-2300(03)00047-3 1:CAS:528:DC%2BD3sXls1Cjs7w%3D (Pubitemid 36873799)
38. S Bjorkman 2005 Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs Br J Clin Pharmacol 59 691 704 15948934 10.1111/j.1365-2125.2004.02225.x (Pubitemid 40835503)
39. G Ginsberg 2004 Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents J Toxicol Environ Health A 67 297 329 14713563 10.1080/15287390490273550 1:CAS:528:DC%2BD2cXhs1Cgtw%3D%3D (Pubitemid 38200033)
40. BL Lum S Kaubisch AM Yahanda KM Adler L Jew MN Ehsan NA Brophy J Halsey MP Gosland BI Sikic 1992 Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance J Clin Oncol 10 1635 1642 1403041 1:STN:280:DyaK3s%2FhvFCitQ%3D%3D (Pubitemid 23057994)
41. NJ Lacayo BL Lum DL Becton H Weinstein Y Ravindranath MN Chang L Bomgaars SJ Lauer BI Sikic GV Dahl 2002 Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia Leukemia 16 920 927 11986955 10.1038/sj.leu.2402455 1:CAS:528:DC%2BD38XksFCktbs%3D (Pubitemid 34537566)
42. HD Thomas DJ Porter I Bartelink JR Nobbs M Cole S Elliott DR Newell AH Calvert M Highley AV Boddy 2002 Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide Br J Clin Pharmacol 53 83 91 11849199 10.1046/j.0306-5251.2001.01513.x 1:CAS:528:DC%2BD38XhtFWrs7Y%3D (Pubitemid 34117743)
43. JH Rodman 1994 Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation J Clin Oncol 12 2390 2397 7964955 1:STN:280:DyaK2M%2FlsValtg%3D%3D (Pubitemid 24346712)
44. A Thiery-Vuillemin E Dobi T Nguyen B Royer D Montange T Maurina E Kalbacher F Bazan C Villanueva M Demarchi L Chaigneau A Ivanaj X Pivot 2010 Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors Anticancer Drugs 21 958 962 20856105 10.1097/CAD. 0b013e32833fc0be 1:CAS:528:DC%2BC3cXht1GkurzM
45. F Fenneteau J Turgeon L Couture V Michaud J Li F Nekka 2009 Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination Theor Biol Med Model 6 2 19146691 10.1186/1742-4682-6-2
46. T Nishimura Y Kato N Amano M Ono Y Kubo Y Kimura H Fujita A Tsuji 2008 Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat Pharm Res 25 2467 2476 18626752 10.1007/s11095-008-9658-4 1:CAS:528:DC%2BD1cXht1aisbrI